STOCK TITAN

Burcon Achieves First Commercial Production of Pea Protein

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Positive)
Tags
Burcon NutraScience (BRCNF) has achieved its first commercial production of Peazazz C pea protein at its Galesburg facility in Illinois. The company expects revenues of $1-3M in 2025 and over $10M in 2026, with positive cash flow projected for 2026. Additionally, Burcon announced a 20:1 share consolidation effective June 11, 2025, aimed at improving share marketability and attracting new investors. The consolidation will reduce the number of outstanding shares from 253,761,444, with fractional shares being rounded up if 0.5 or greater and down if less than 0.5. The company's management views this milestone as crucial for meeting customer demand and generating scalable revenue opportunities, while the consolidation is expected to optimize capital structure and enhance long-term shareholder value.
Burcon NutraScience (BRCNF) ha realizzato la sua prima produzione commerciale di proteina di pisello Peazazz C presso il suo stabilimento di Galesburg, Illinois. L'azienda prevede ricavi tra 1 e 3 milioni di dollari nel 2025 e oltre 10 milioni nel 2026, con un flusso di cassa positivo previsto per il 2026. Inoltre, Burcon ha annunciato una consolidazione azionaria 20:1 a partire dall'11 giugno 2025, volta a migliorare la commerciabilità delle azioni e ad attrarre nuovi investitori. La consolidazione ridurrà il numero di azioni in circolazione da 253.761.444, arrotondando le frazioni di azioni per eccesso se pari o superiori a 0,5 e per difetto se inferiori a 0,5. La direzione aziendale considera questo traguardo fondamentale per soddisfare la domanda dei clienti e generare opportunità di ricavi scalabili, mentre la consolidazione dovrebbe ottimizzare la struttura del capitale e aumentare il valore a lungo termine per gli azionisti.
Burcon NutraScience (BRCNF) ha logrado su primera producción comercial de proteína de guisante Peazazz C en su planta de Galesburg, Illinois. La empresa espera ingresos de entre 1 y 3 millones de dólares en 2025 y más de 10 millones en 2026, con un flujo de caja positivo proyectado para 2026. Además, Burcon anunció una consolidación de acciones 20:1 efectiva a partir del 11 de junio de 2025, destinada a mejorar la comercialización de las acciones y atraer nuevos inversores. La consolidación reducirá el número de acciones en circulación desde 253,761,444, redondeando las fracciones de acciones hacia arriba si son 0,5 o mayores y hacia abajo si son menores a 0,5. La dirección de la empresa considera este hito crucial para satisfacer la demanda de los clientes y generar oportunidades de ingresos escalables, mientras que la consolidación se espera que optimice la estructura de capital y aumente el valor a largo plazo para los accionistas.
Burcon NutraScience(BRCNF)는 일리노이 주 게일즈버그에 위치한 시설에서 Peazazz C 완두콩 단백질의 첫 상업 생산을 달성했습니다. 회사는 2025년에 100만 달러에서 300만 달러의 매출을 예상하며, 2026년에는 1,000만 달러 이상의 매출과 긍정적인 현금 흐름을 전망하고 있습니다. 또한 Burcon은 2025년 6월 11일부터 효력이 발생하는 20:1 주식 병합을 발표했으며, 이는 주식의 시장성 향상과 신규 투자자 유치를 목표로 합니다. 병합으로 인해 발행 주식 수는 253,761,444주에서 감소하며, 0.5 이상인 소수 주식은 올림, 0.5 미만은 내림 처리됩니다. 회사 경영진은 이번 이정표가 고객 수요 충족과 확장 가능한 수익 창출 기회에 매우 중요하다고 보고 있으며, 병합은 자본 구조 최적화와 장기 주주 가치 증대를 기대하고 있습니다.
Burcon NutraScience (BRCNF) a réalisé sa première production commerciale de protéine de pois Peazazz C dans son usine de Galesburg, Illinois. La société prévoit des revenus de 1 à 3 millions de dollars en 2025 et plus de 10 millions en 2026, avec un flux de trésorerie positif attendu pour 2026. De plus, Burcon a annoncé une consolidation d’actions au ratio de 20 pour 1, effective à partir du 11 juin 2025, visant à améliorer la négociabilité des actions et à attirer de nouveaux investisseurs. Cette consolidation réduira le nombre d’actions en circulation à partir de 253 761 444, les fractions d’actions étant arrondies à l’unité supérieure si elles sont égales ou supérieures à 0,5, et à l’unité inférieure si elles sont inférieures à 0,5. La direction considère cette étape comme cruciale pour répondre à la demande des clients et générer des opportunités de revenus évolutifs, tandis que la consolidation devrait optimiser la structure du capital et accroître la valeur à long terme pour les actionnaires.
Burcon NutraScience (BRCNF) hat die erste kommerzielle Produktion des Erbsenproteins Peazazz C in seiner Anlage in Galesburg, Illinois, erreicht. Das Unternehmen erwartet für 2025 Umsätze zwischen 1 und 3 Millionen US-Dollar und über 10 Millionen US-Dollar im Jahr 2026, mit einem positiven Cashflow, der für 2026 prognostiziert wird. Zudem kündigte Burcon eine 20:1-Aktienzusammenlegung an, die ab dem 11. Juni 2025 in Kraft tritt und darauf abzielt, die Handelbarkeit der Aktien zu verbessern und neue Investoren anzuziehen. Durch die Zusammenlegung wird die Anzahl der ausstehenden Aktien von 253.761.444 verringert, wobei Bruchteile von Aktien aufgerundet werden, wenn sie 0,5 oder mehr betragen, und abgerundet, wenn sie darunter liegen. Die Unternehmensleitung sieht diesen Meilenstein als entscheidend an, um die Kundennachfrage zu erfüllen und skalierbare Umsatzmöglichkeiten zu schaffen, während die Zusammenlegung die Kapitalstruktur optimieren und den langfristigen Wert für die Aktionäre steigern soll.
Positive
  • Successful launch of commercial pea protein production at Galesburg facility
  • Revenue projection of $1-3M for 2025 and $10M+ for 2026
  • Positive cash flow expected by 2026
  • Strategic 20:1 share consolidation to improve marketability and attract investors
Negative
  • Share consolidation may indicate previous stock price challenges
  • Revenue generation still in early stages with modest 2025 projections
  • Several months needed before reaching significant production scale

Vancouver, British Columbia--(Newsfile Corp. - June 9, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein innovation, is pleased to announce the successful first commercial production run of its next-generation Peazazz®C pea protein at its Galesburg facility in Illinois, USA.

"The successful startup of our Galesburg facility marks a key operational milestone in Burcon's commercial scale-up," said Kip Underwood, Burcon's chief executive officer. "In less than 90 days since commissioning, our team has brought next-generation protein production online, enabling us to meet accelerating customer demand and unlock scalable revenue opportunities."

Burcon remains on track to achieve key operational and financial milestones through 2025/2026. The Company anticipates the following revenue targets:

  • $1-3 million in revenue for calendar year 2025

  • $10+ million in revenue for calendar year 2026

  • Positive cash flow projected to be achieved in calendar year 2026

With commercial production now underway and ramping through the second half of 2025, Burcon is actively progressing customer supply agreements that will support long-term recurring revenue. The Galesburg facility provides meaningful capacity to scale production and positions the Company to execute its growth plan, expand market penetration, and drive long-term enterprise value.

Share Consolidation

Burcon announces it has consolidated its issued and outstanding common shares (the "Shares") at a ratio of twenty (20) pre-consolidation Shares to one (1) post-consolidation share (the "Consolidation").

The Shares are expected to commence trading on the TSX on a post-Consolidation basis at the start of trading on June 11, 2025. The Company's name and trading symbol will remain the same after the Consolidation.

Peter H. Kappel, Burcon's Chairman of the board commented: "We are confidently advancing our strategic plan, and the Consolidation marks a key step in optimizing our capital structure and unlocking long-term value for shareholders. This initiative is designed to attract new investors, improve the marketability of our common shares, and position Burcon for future growth."

The Consolidation has been approved by the board of directors of Burcon (the "Board") and by shareholders of the Company (the "Shareholders") pursuant to the share consolidation authorizing resolution approved at the Company's most recent annual general and special meeting of Shareholders held on September 18, 2024. As discussed in greater detail in the management information circular of the Company dated August 1, 2024, the Board believes that implementing the Consolidation is in the best interests of the Company as it could lead to increased interest by a wider audience of potential investors and result in less volatility resulting in a more efficient market for the Common Shares. The Board also regularly evaluates other opportunities to increase the Company's access to capital markets and the Consolidation could allow the Company to access other exchanges that have minimum listing requirements.

No fractional Shares will be issued under the Consolidation. The holdings of any Shareholder who would otherwise be entitled to receive a fractional Share as a result of the Consolidation shall be rounded up to the next higher whole number if the fraction is 0.5 or greater and rounded down to the next lower whole number if the fraction is less than 0.5. The Consolidation will not affect any Shareholder's percentage ownership in the Company other than by the minimal effect of the aforementioned elimination of fractional Shares, even though such ownership will be represented by a smaller number of Shares. Instead, the Consolidation will reduce proportionately the number of Shares held by all Shareholders. There were 253,761,444 common shares of Burcon outstanding prior to the Consolidation.

Shareholders who hold uncertificated Shares (including Shares held through a brokerage account and/or not represented by a physical share certificate), will have their holdings electronically adjusted by the Company's transfer agent or by their brokerage firms, banks, trust or other nominees. Such Shareholders do not need to take any additional actions to exchange their pre-Consolidation Shares for post-Consolidation Shares. Letters of transmittal are being mailed to all registered Shareholders holding share certificates with instructions on how to exchange existing share certificate(s) for new share certificate(s). A copy of the letter of transmittal will also be available on the Company's profile on SEDAR+.

The Company's new CUSIP number for the post-Consolidation Shares will be 120831300 and its new ISIN number is CA1208313009.

The exercise price and number of Common Shares issuable upon the exercise of Burcon's outstanding warrants will be proportionately adjusted to reflect the Consolidation in accordance with the terms of such securities.

About Burcon NutraScience Corporation

Burcon is a global technology leader in high-performance plant-based proteins for the food and beverage industry. Our commercial ingredients offer superior taste, texture, and functionality-ideal for formulators seeking next-generation protein solutions. Backed by over two decades of innovation, Burcon holds an extensive patent portfolio covering novel proteins derived from pea, canola, soy, hemp, sunflower, and other plant sources. As a key player in the rapidly growing plant-based market, Burcon is committed to sustainability and to creating best-in-class protein solutions that are better for people and the planet. Learn more at www.burcon.ca.

Forward-Looking Information Cautionary Statement

The TSX has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements or forward-looking information can be identified by words such as "anticipate," "aim", "intend," "plan," "goal," "project," "estimate," "expect," "believe," "future," "likely," "may," "should," "could," "will" and similar references to future periods. All statements included in this release, other than statements of historical fact, are forward-looking statements. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon's plans and expectations include the implementation of our business model and growth strategies; trends and competition in our industry our future business development, financial condition and results of operations and our ability to obtain financing cost-effectively; potential changes of government regulations, and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled "Risk Factors" in Burcon's annual information form for the year ended March 31, 2024 and its other public filings with Canadian securities regulators on SEDAR+ at www.sedarplus.ca. This list is not exhaustive of the factors that may affect any of the Company's forward-looking statements or information. Any forward-looking statement or information speaks only as of the date on which it was made, and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and, accordingly, investors should not rely on such statements.

Industry and Investor Contact
Paul Lam
Director, Investor Relations and Communications
Burcon NutraScience Corporation
490 - 999 West Broadway, Vancouver, BC, V5Z 1K5
Tel (604) 733-0896, Toll-free (888) 408-7960
plam@burcon.ca 
www.burcon.ca

Media Contact:
Steve Campbell, APR
President
Campbell & Company Public Relations
Tel (604) 888-5267
TECH@CCOM-PR.COM

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/254863

FAQ

What are Burcon's (BRCNF) revenue projections for 2025 and 2026?

Burcon projects revenue of $1-3 million for 2025 and over $10 million for 2026, with positive cash flow expected in 2026.

What is the ratio of Burcon's share consolidation and when is it effective?

Burcon announced a 20:1 share consolidation, effective June 11, 2025, reducing from 253,761,444 outstanding shares.

What product has Burcon started producing at its Galesburg facility?

Burcon has begun commercial production of its next-generation Peazazz C pea protein at its Galesburg facility in Illinois.

When does Burcon (BRCNF) expect to achieve positive cash flow?

Burcon expects to achieve positive cash flow in calendar year 2026.

How will Burcon's share consolidation affect shareholders?

The consolidation won't affect shareholders' percentage ownership except for minimal fractional share adjustments, with fractions of 0.5 or greater rounded up and less than 0.5 rounded down.
Burcon Nutrascience Corp

OTC:BRCNF

BRCNF Rankings

BRCNF Latest News

BRCNF Stock Data

16.24M
175.42M
29.63%
1.89%
0.11%
Packaged Foods
Consumer Defensive
Link
Canada
Vancouver